Characteristics of adult retroperitoneal lymphangioma: a single center Chinese cohort study of 15 cases
Discover Oncology · 04.07.2024 · 15 (1)
DOI: 10.1007/s12672-024-01143-5 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Discover Oncology, online erschienen am 04.07.2024. Verfasst von Jie Liu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hepatobiliary and Pancreatic Surgery, Department of General Surgery, The First Affiliated Hospital, Zhejiang University School of Medicin…. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Zhejiang Provincial Traditional Medicine and Technology Project, Zhejiang Provincial Health Science and Technology Project.
Abstract (Originalsprache)
Background
Lymphangioma is a rare cystic tumor that occurs across different locations. Retroperitoneal lymphangioma accounts for about 1% of all lymphangiomas. In this study, we report the clinicopathological features of retroperitoneal lymphangioma and describe our experience in treating this disease.
Methods
We collected clinical data from all patients who were pathologically diagnosed with retroperitoneal lymphangioma at Zhejiang Provincial People's Hospital, between June 2013 and August 2022.
Results
The 7 and 8 male and female patients analyzed herein had a mean age of 48.6 (SD 14.24) years at diagnosis. The mean duration of follow-up was 4.7 years. Among them, 66.67% were asymptomatic, with the rest manifesting abdominal pain, nausea, low back pain and elevated blood pressure as the main symptoms. Preoperative diagnosis and evaluation of cysts were mainly performed via computed tomography (CT) (n = 10, 66.67%) or magnetic resonance imaging (MRI) (n = 8, 53.33%). All patients were completely resected following surgery. Immunohistochemical analysis, performed on 6 patients, revealed that they were positive for D2-40. A total of 4, 4 and 3 patients were positive for CD31, CD34 and SMA, respectively. Moreover, the study cohort had an average postoperative hospital stay of 6.6 days. Follow up, after the end of the study, revealed no relapse in any of the 15 patients.
Conclusions
Lymphangioma is a benign tumor of the lymphatic system. Although typical imaging features can be accurate for preoperative diagnosis, histological examination is crucial to final confirmation. Complete surgical resection is the best option to limit the risk of recurrence in cases with symptomatic lesions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hepatobiliary and Pancreatic Surgery, Department of General Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, Zhejiang, China.
- General Surgery, Cancer Center, Department of Hepatobiliary & Pancreatic Surgery and Minimally Invasive Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, 3…
- Division of Hepatobiliary and Pancreatic Surgery, Department of General Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, Zhejiang, China. shusenzheng@zju.edu.cn.
Förderung
- Zhejiang Provincial Traditional Medicine and Technology Project
- Zhejiang Provincial Health Science and Technology Project
Zitieren
APA
Liu, J., Zhong, Z. H., & Zheng, S. S. (2024). Characteristics of adult retroperitoneal lymphangioma: a single center Chinese cohort study of 15 cases. Discover Oncology, 15(1). https://doi.org/10.1007/s12672-024-01143-5
Vancouver
Liu J, Zhong ZH, Zheng SS. Characteristics of adult retroperitoneal lymphangioma: a single center Chinese cohort study of 15 cases. Discover Oncology. 2024;15(1). doi:10.1007/s12672-024-01143-5
BibTeX
@article{Liu2024,
author = {Liu, Jie and Zhong, Zhi-Han and Zheng, Shu-Sen},
title = {Characteristics of adult retroperitoneal lymphangioma: a single center Chinese cohort study of 15 cases},
journal = {Discover Oncology},
year = {2024},
volume = {15},
number = {1},
doi = {10.1007/s12672-024-01143-5}
}
EUVIMED